Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
137Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $40.0K | $-62.15M | $-3.23 |
Social Signal Score
Earnings
Fri, Nov 13(in 3 months)
Consensus estimate $-0.23 per share
Typical surprise -47.6% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.58 vs $-0.12miss
- Mon, May 18$-0.38 vs $-0.22miss
- Tue, Mar 31$-0.40 vs $-0.37miss
- Fri, Nov 14$-0.45 vs $-0.37miss
Estimates and results for NTHI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
NTHIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (4)
- Newsnewsfilecorp.com·1d ago·Neutral
Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26 Dallas, Texas--(Newsfile Corp. - August 13, 2026) - NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI).
View source ↗ - Newsglobenewswire.com·2d ago·Negative
The Nose Knows: Why NeOnc's Patent Portfolio Could Make NTHI More Than a One-Drug Biotech DENVER, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings' (NASDAQ: NTHI) August 12 headline was impossible to miss, but another interesting solution may be hiding in plain sight: while NeOnc produced encouraging data for one cancer drug, it also generated human clinical evidence around a non-invasive intranasal delivery strategy designed to reach the brain without relying on conventional system…
View source ↗ - Newsglobenewswire.com·3d ago·Neutral
Targeting The Mutant: NTHI's NEO100 Data Could Open a New Front in the Fight Against Brain Cancer DALLAS, Aug. 12, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has delivered the kind of clinical update that can change the conversation around a small biotechnology company: its Phase 2a study of intranasal NEO100 in recurrent IDH1-mutant high-grade glioma met its primary endpoint, with six-month progression-free survival of 48.9% versus a pre-specified 20% benchmark for stan
View source ↗ - Newsnewsfilecorp.com·4d ago·Positive
NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence Houston, Texas--(Newsfile Corp. - August 11, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) is set up for a potential high impact catalyst day with what market observers are describing as a classic triple confluence setup. The company will release topline Phase 2a results for its intranasal NEO100 therapy in recurrent IDH1-mutant high-grade glioma, a difficult-to-treat form of brain cancer on Wednesday, August 12 at 8:30 a.m.
View source ↗